Evogene to Present Innovative Approach for Improving Cannabis for Medical Needs at CannaTech Summit07/03/2017
Rehovot, Israel – March 07, 2017 – Evogene Ltd. (NASDAQ, TASE: EVGN), a leading company for the improvement of crop productivity and economics for food, feed and fuel, announced today that Mr. Yuval Ben-Galim, Evogene's COO, will present at the CannaTech 2017 annual cannabis summit, taking place in Tel-Aviv, Israel on March 21st. The summit will focus on acceleration of cannabis innovation, with wide spectrum of global industry leaders spanning from science to government.
Cannabis is now being widely acknowledged for its potential to facilitate medicinal benefits. One of the major limitations in the field is developing various stable cannabis strains that contain the desired active components that meet precise medicinal needs for different diseases and indications. As we recently disclosed, cannabis is one of the crops Evogene is evaluating for the extension of its program focus. At the conference, Mr. Ben-Galim will present Evogene's approach, which utilizes the Company’s predictive biology technology platform to develop innovative cannabis strains that are specifically generated for medicinal requirements, to potentially address this challenge.
About Evogene Ltd.:
Evogene (NASDAQ, TASE: EVGN) is a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries. The Company operates in three key target markets: improved seed traits (addressing yield increase, tolerance to environmental stresses and resistance to insects and diseases); innovative ag-chemicals (developing novel herbicide solutions for weed control); and ag-biologicals. Evogene has collaborations with world-leading seed and ag-chemical companies. For more information, please visit www.evogene.com or contact the Company at firstname.lastname@example.org.
This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", “expects”, "intends", “anticipates”, “plans”, “believes”, “scheduled”, “estimates” or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene’s reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
Press releases for 2016
- Evogene to Present Innovative Approach for Improving Cannabis for Medical Needs at CannaTech Summit
- Evogene Reports Fourth Quarter and Full Year 2016 Financial Results
- Evogene and ICL Innovation Sign Collaboration for Development of Crop Enhancers
- Evogene Fourth Quarter and Full Year 2016 Earnings Announcement Schedule
- Evogene to Transfer Stock Exchange Listing to Nasdaq
- Evogene Reports Third Quarter 2016 Financial Results
- Evogene Announces Positive Field Trial Results in Ag-biologicals Program
- Evogene Third Quarter 2016 Earnings Announcement Schedule
- Evogene and IMAmt Sign Collaboration for Genomic Promoter Discovery and Validation in Cotton
- Evogene Announces Joint Microbial Diversity Activity with University of Missouri
- Evogene Announces Participation at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 11-13th, 2016
- Evogene Appoints a New Member to Board of Directors and a New Chief Operating Officer
- Evogene Reports Second Quarter 2016 Financial Results
- Evogene to Participate at Piper Jaffray Global Agriculture Symposium
- Evogene Second Quarter 2016 Earnings Announcement Schedule
- Evogene to Present at Crops and Chemicals 2016 Conference
- Evogene Reports Financial Results for the First Quarter of 2016
- Evogene and Marrone Bio Innovations Disclose Positive Results in Insect Control Collaboration
- Evogene to Present the Potential of Integrating Novel Genome Editing Technology with its Core Capabilities for Improved Seed Traits at Plant Genomics Congress
- Evogene’s First Quarter 2016 Earnings Announcement Schedule
- Evogene Files Annual Report for the Year Ended December 31, 2015
- Evogene Selected for Photosynthesis Research Consortium within European Horizon 2020 Program
- Evogene Reports Fourth Quarter and Full Year 2015 Financial Results
- Evogene Discloses Positive Results in Yield Improvement Collaboration with Monsanto Utilizing Novel 'Trait-First' Methodology
- Evogenes Fourth Quarter with Full Year 2015 Earnings Announcement Schedule